
Preclinical Oncology Services
An unparalleled portfolio of oncology CRO services and clinical specialty testing solutions to accelerate drug development
Offerings
Explore Our Services
With the most up-to-date and relevant bank of preclinical research models mirroring clinical trial patient populations, a large portfolio of novel proprietary platforms, and validated clinical specialty testing expertise, Champions is the ideal partner to deliver success and accelerate your drug development process.

Solid Tumor PDX
The most diverse, annotated, and clinically relevant living bank for solid tumor oncology research.
PDX

Blood Cancer PDX
World's largest living bank of primary hematological tumors and leukemia xenograft tumor models for preclinical testing.
PDX

Pretreated PDX
Discover Champions Oncology's 700+ pretreated PDX models for advanced cancer therapies, replicating patient responses and clinical outcomes.
PDX

PDX Model Bank
Search through our extensive and highly characterized PDX bank.
PDX

CDX
Discover Champions’ validated CDX models for oncology. Proof of concept, ADC target validation, and translational insights with Cell Line Select Tool.
CDX

CDX Model Bank
Streamline CDX model selection with powerful filters for tumor indication and genetic profile.
CDX

Ex Vivo
Our TumorGraft3D platform supports selected ex vivo studies using low-passage, PDX-derived 3D tumor models
Ex Vivo

Hematological Cancer Screen
Champions' Hematological VitroScreens offer a quick, cost-effective solution to test your therapeutics in an ex vivo hematologic assay.
Ex Vivo

3D Solid Tumor Models
Leverage over 1,400 clinically relevant TumorGraft3D models generated from deeply characterized PDX models for advanced ex vivo evaluation of novel cancer therapeutics.
Ex Vivo

Syngeneic
Explore Champions Oncology's extensive collection of well-characterized syngeneic models for the preclinical testing of your innovative immunotherapies.

Humanized
Cutting-edge humanized mouse models tailored to harness the power of the human immune system and unveil the full potential of your preclinical immunotherapy research

Get started